BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (BCRX) has granted stock options and restricted stock units (RSUs) to eight newly-hired employees as employment inducements. The compensation committee approved options to purchase 22,575 shares and RSUs covering 27,550 shares of common stock, effective January 31, 2025.
The stock options were granted at an exercise price of $7.90 per share, matching the closing price on the grant date. Both options and RSUs will vest in four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term and are subject to BioCryst's Inducement Equity Incentive Plan terms.
BioCryst Pharmaceuticals (BCRX) ha concesso opzioni su azioni e unità di azioni riservate (RSU) a otto nuovi dipendenti come incentivo per l'assunzione. Il comitato per la compensazione ha approvato opzioni per l'acquisto di 22.575 azioni e RSU che coprono 27.550 azioni di azioni ordinarie, con effetto dal 31 gennaio 2025.
Le opzioni su azioni sono state concesse a un prezzo di esercizio di $7,90 per azione, equivalente al prezzo di chiusura nel giorno della concessione. Sia le opzioni che le RSU matureranno in quattro rate annuali uguali, a partire dal primo anniversario della data di concessione, a condizione che l'impiego continui. Le opzioni su azioni hanno un termine di 10 anni e sono soggette ai termini del Piano di Incentivazione Azionaria di BioCryst.
BioCryst Pharmaceuticals (BCRX) ha otorgado opciones sobre acciones y unidades de acciones restringidas (RSU) a ocho nuevos empleados como incentivos de contratación. El comité de compensación aprobó opciones para comprar 22,575 acciones y RSUs que cubren 27,550 acciones de acciones ordinarias, con efecto a partir del 31 de enero de 2025.
Las opciones sobre acciones se concedieron a un precio de ejercicio de $7.90 por acción, coincidiendo con el precio de cierre en la fecha de concesión. Tanto las opciones como las RSU se harán efectivas en cuatro pagos anuales iguales, comenzando desde el primer aniversario de la fecha de concesión, siempre que el empleo continúe. Las opciones sobre acciones tienen un plazo de 10 años y están sujetas a los términos del Plan de Incentivo de Equidad por Inducción de BioCryst.
BioCryst Pharmaceuticals (BCRX)는 신규 채용된 8명의 직원에게 고용 유인을 위해 스톡 옵션과 제한 주식 단위(RSU)를 부여했습니다. 보상 위원회는 22,575주의 주식을 구매할 수 있는 옵션과 27,550주의 보통주를 포함하는 RSU를 승인하였으며, 이는 2025년 1월 31일부터 시행됩니다.
스톡 옵션은 주당 $7.90의 행사 가격으로 부여되었으며, 이는 부여 날짜의 종가와 일치합니다. 옵션과 RSU는 부여 날짜의 1주년부터 시작하여 4회에 걸쳐 동등한 연간 할부로 발생하게 되며, 지속적인 고용이 전제 조건입니다. 스톡 옵션은 10년의 유효 기간을 가지며 BioCryst의 유인 주식 보상 계획 조건에 따라야 합니다.
BioCryst Pharmaceuticals (BCRX) a accordé des options d'actions et des unités d'actions restreintes (RSU) à huit nouveaux employés en tant qu'incitations à l'embauche. Le comité de rémunération a approuvé des options d'achat de 22.575 actions et des RSU couvrant 27.550 actions de l'actions ordinaires, avec effet au 31 janvier 2025.
Les options d'actions ont été accordées à un prix d'exercice de 7,90 $ par action, correspondant au prix de clôture à la date d'attribution. Les options et les RSU seront acquises en quatre annuités égales, à partir du premier anniversaire de la date d'attribution, sous réserve d'un emploi continu. Les options d'actions ont une durée de 10 ans et sont soumises aux conditions du Plan d'Incitation en Capital de BioCryst.
BioCryst Pharmaceuticals (BCRX) hat acht neu eingestellten Mitarbeitern als Einstellungsmotivationen Aktienoptionen und eingeschränkte Aktieneinheiten (RSU) gewährt. Der Vergütungsausschuss genehmigte Optionen zum Erwerb von 22.575 Aktien und RSUs, die 27.550 Aktien des Stammkapitals abdecken, wirksam ab dem 31. Januar 2025.
Die Aktienoptionen wurden zu einem Ausübungspreis von 7,90 $ pro Aktie gewährt, was dem Schlusskurs am Gewährungstag entspricht. Sowohl die Optionen als auch die RSUs werden in vier gleichen jährlichen Raten anfallen, beginnend mit dem einjährigen Jubiläum des Gewährungstags, vorausgesetzt, die Beschäftigung bleibt bestehen. Die Aktienoptionen haben eine Laufzeit von 10 Jahren und unterliegen den Bedingungen des Anreiz-Eigenkapitalvergütungsplans von BioCryst.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 22,575 shares, and restricted stock units (RSUs) covering an aggregate of 27,550 shares, of BioCryst common stock. The options and RSUs were granted as of January 31, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
How many shares of BCRX stock options were granted to new employees in January 2025?
What is the exercise price for BCRX stock options granted on January 31, 2025?
How many RSUs did BCRX grant to new employees in January 2025?
What is the vesting schedule for BCRX's January 2025 stock options and RSUs?
